396 related articles for article (PubMed ID: 29136244)
1. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
[TBL] [Abstract][Full Text] [Related]
2. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
3. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
4. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
6. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
7. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
[TBL] [Abstract][Full Text] [Related]
8. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
[TBL] [Abstract][Full Text] [Related]
10. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
11. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
[TBL] [Abstract][Full Text] [Related]
12. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
13. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
15. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
17. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells.
Yoo SM; Lee CJ; Kang HC; Lee HS; Lee JY; Kim KD; Kim DJ; An HJ; Cho YY
Mol Carcinog; 2019 Jul; 58(7):1221-1233. PubMed ID: 30887599
[TBL] [Abstract][Full Text] [Related]
18. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
19. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.
Sami A; Karsy M
Tumour Biol; 2013 Aug; 34(4):1991-2002. PubMed ID: 23625692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
